Anti-programmed cell death 1 (anti-PD-1) autoantibody as a biomarker for prognosis of cancer (IMAGE)

Okayama University

Anti-programmed cell death 1 (anti-PD-1) autoantibody as a biomarker for prognosis of cancer

Caption

The researchers explored the correlation between serum levels of anti-PD-1 autoantibody and overall survival rates in patients with liver cancer who received Atezo/Bev as first-line therapy.

Credit

Dr. Akinobu Takaki from Okayama University, Japan

Usage Restrictions

Do not reuse without permission

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.